9 June 2021
AVICENNA, AI medical imaging specialist, honored again with a new FDA and CE mark for CINA Chest, its brand new solution for pulmonary embolism and aortic dissections.
Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies.
The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks thanks to high-performance tools. Its first generation of products (“CINA” products) leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Since its inception in 2018 the Company has gained a lot of traction on the business and regulatory issues thanks to several FDA and CE mark approvals and worldwide partnerships with leading industrials in the medical imaging business.
NeOse Advance & Aryballe Suite of software solutions enable customers to harness the power of odor with greater reliability, scalability and accessibility